Bonesupport Holding Logo
SE0009858152
A2DTSD
BONEX.ST

Bonesupport Holding

A carregar cotações...

Previsão

Não temos dados de analistas para esta empresa.

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Bonesupport surges after CMS decision for CERAMENT G and expects strong growth

    Bonesupport’s stock rose about 35% within a month, supported by improved reimbursement in the US from CMS for the antibiotic-containing bone substitute CERAMENT G. Analysts at ABG Sundal Collier expect an organic sales increase of 31% for Q1; results will be published on April 22. CEO Torbjörn Sköld confirms the 2026 guidance of more than 35% revenue growth, driven by further market penetration in foot/ankle, trauma and revision arthroplasty. Technically, the stock has moved above the 200-day moving average; investors are holding positions and betting on strong quarterly figures. » Mais em deraktionaer.de


  • Bonesupport targets at least 35% revenue growth in 2026 after strong Q4

    Bonesupport reports a Q4 2025 revenue increase of 36% to SEK 313 million and records a sales increase of nearly 40% for 2025 overall. The company issues guidance for 2026 of at least 35% revenue growth at constant exchange rates and cites strong demand in the US for CERAMENT products as well as potential from indication expansions. Gross margins are typically around 90%; the stock rises by almost 20% after the outlook and reaches its highest level since October. » Mais em deraktionaer.de


  • Bonesupport records strong revenue and margin growth, shares fall after quarterly results

    Bonesupport reported Q3 2025 net sales of SEK 294.1m (+24% yoy; +34% currency-adjusted) and an adjusted operating margin of 27%, driven by a strong US business and growth in the antibiotic-releasing CERAMENT products. Operating cash flow remained robust and net cash stood at SEK 379.0m at quarter-end. The company is preparing market entries in spine surgery and revision arthroplasty, received NTAP approval for CERAMENT G and reiterated full-year guidance of >40% currency-adjusted revenue growth. Despite operational progress, the stock fell sharply after the presentation, reflecting investor concerns about currency headwinds, possible regulatory hurdles and market risks. » Mais em de.investing.com


  • Bonesupport achieves record profitability and currency-adjusted revenue growth of 40% in Q2 2025

    Bonesupport reports net sales of SEK 284m for Q2 2025 (+29% y/y; +40% currency-adjusted) and adjusted operating income of SEK 62m, the highest margin in the company’s history (EBIT margin 26%). The North American market drives growth (SEK 236m, +36% or +49% currency-adjusted), led by CERAMENT G with USD 18.3m in sales (+84%). Operating cash flow was SEK 50m; the company targets currency-adjusted revenue growth of over 40% for 2025 and plans to launch CERAMENT BVF for spinal applications in North America in December 2025. » Mais em de.investing.com


  • Bonesupport Holding AB reports strong revenue growth in the second quarter of 2025

    Bonesupport Holding AB recorded a 29% increase in revenue to SEK 284.4 million in the second quarter of 2025, with a stable gross margin of around 95%. The US market showed particularly strong growth, with Cerement G sales rising by 84%, while the company reaffirmed its outlook for continued revenue growth. Despite regulatory and market challenges, the outlook remains positive, supported by product innovation and strategic expansion. » Mais em de.investing.com

Em 2022, Bonesupport Holding já distribuiu € 0,26 em dividendos. A última distribuição ocorreu em março de 2022.

Dados financeiros da empresa

No último trimestre, Bonesupport Holding registou receitas de € 36,06 mi e um ganho líquido de € 8,15 mi
(EUR) setembro de 2026
YoY
Receitas 36,06 mi 35,51%
Ganho bruto 33,17 mi 34,18%
Ganho líquido 8,15 mi 160,94%
EBITDA 10,47 mi 68,69%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 1,86 bi
Número de ações
65,22 mi
Máximo/mínimo de 52 semanas
€ 30,44 - € 15,03
Dividendos Não
Beta
0,49
PER (PE Ratio)
77,14
PEG (PEG Ratio)
0,98
P/VC (PB Ratio)
20,98
P/V (PS Ratio)
14,83

Perfil da empresa

A Bonesupport Holding AB (publ), uma empresa de ortobiológicos, desenvolve e comercializa substitutos injetáveis de enxerto ósseo à base de biocerâmica para o tratamento de defeitos ósseos na Europa, na América do Norte e a nível internacional. A empresa disponibiliza o CERAMENT Bone Void Filler, um preenchimento ósseo sintético injetável, moldável e perfurável que inclui hidroxiapatite, sulfato de cálcio e o agente de contraste radiológico iohexol; o CERAMENT G, um substituto injetável de enxerto ósseo em cerâmica com gentamicina; e o CERAMENT V, um preenchimento ósseo sintético injetável com vancomicina. A empresa desenvolve também candidatos a produtos pré-clínicos para promover a regeneração óssea, com foco em traumatismos, artroplastia de revisão, osteomielite crónica, artroplastia de revisão, e oncologia, bem como em infeções ósseas e do pé devidas à diabetes. A empresa foi fundada em 1999 e tem sede em Lund, na Suécia.

Nome
Bonesupport Holding
CEO
Torbjorn Skold
Sede Lund, sn
Suécia
Site
Setor
Cuidados de saúde
Indústria
Biotecnologia
Entrada em bolsa
14/12/2017
Colaboradores 160

Símbolos de ticker

Bolsa Símbolo
Sto
BONEX.ST
London Stock Exchange
0RQO.L
XETRA
2B4.F
Pnk
BOEUF
Frankfurt
2B4.F
Düsseldorf
2B4.DU
London
0RQO.L
Stockholm
BONEX.ST
München
2B4.MU
🍪

Parqet  utiliza cookies. Saber mais